Header

UZH-Logo

Maintenance Infos

Browse by Creators

Navigate back| Up a level
Export as
Number of items: 40.

Hirschmann, A; Lupatsch, J E; Schwenkglenks, M; Panje, C M; Matter-Walstra, K; Espeli, V; Dedes, K J; Siano, M (2018). Cost-effectiveness of nivolumab in the treatment of head and neck cancer. Oral Oncology, 87:104-110.

Matter-Walstra, K W; Achermann, R; Rapold, R; Klingbiel, D; Bordoni, A; Dehler, S; Konzelmann, I; Mousavi, M; Clough-Gorr, K M; Szucs, T; Schwenkglenks, M; Pestalozzi, B C (2017). Days spent in acute care hospitals at the end of life of cancer patients in four Swiss cantons: a retrospective database study (SAKK 89/09). European Journal of Cancer Care, 26(4):e12453.

Matter-Walstra, K; Braun, R; Kolb, C; Ademi, Z; Dummer, R; Pestalozzi, B C; Schwenkglenks, M (2015). A cost-effectiveness analysis of trametinib plus dabrafenib as first-line therapy for metastatic BRAF V600-mutated melanoma in the Swiss setting. British Journal of Dermatology, 173(6):1462-1470.

Lippuner, K; Grifone, S; Schwenkglenks, M; Schwab, P; Popp, A W; Senn, C; Perrelet, R (2012). Comparative trends in hospitalizations for osteoporotic fractures and other frequent diseases between 2000 and 2008. Osteoporosis International, 23(3):829-839.

Pettengell, R; Johnson, H E; Lugtenburg, P J; Salar Silvestre, A; Dührsen, U; Rossi, F G; Schwenkglenks, M; Bendall, K; Szabo, Z; Jaeger, U (2012). Impact of febrile neutropenia on R-CHOP chemotherapy delivery and hospitalizations among patients with diffuse large B-cell lymphoma. Supportive Care in Cancer, 20(3):647-652.

Johnsen, H E; Haioun, C; Lugtenburg, P J; Salar, A; Jaeger, U; Pettengell, R; Rossi, Fg; Verhoef, G; Schwenkglenks, M; Bendall, K; Duehrsen, U (2012). The importance of G-CSF prophylaxis in R-CHOP-14 therapy for diffuse large B-cell lymphoma in routine clinical practice. Leukemia and Lymphoma, 53(5):982-984.

Joerger, M; Matter-Walstra, K; Früh, M; Kühnel, U; Szucs, T; Pestalozzi, B; Schwenkglenks, M (2011). Addition of cetuximab to first-line chemotherapy in patients with advanced non-small-cell lung cancer: a cost-utility analysis. Annals of Oncology, 22(3):567-574.

Haioun, C; Salar, A; Pettengell, R; Johnsen, H E; Duehrsen, U; Rossi, F G; Verhoef, G; Schwenkglenks, M; Jaeger, U; Hamilton, L; Pujol, B; Lugtenburg, P J (2011). Anemia and erythropoiesis-stimulating agent administration in patients with non-Hodgkin lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisolone ± rituximab chemotherapy: results from an observational study. Leukemia and Lymphoma, 52(5):796-803.

Schwenkglenks, M; Brazier, J E; Szucs, T D; Fox, K A A (2011). Cost-effectiveness of bivalirudin versus heparin plus glycoprotein IIb/IIIa inhibitor in the treatment of non-ST-segment elevation acute coronary syndromes. Value in Health, 14(1):24-33.

Loibl, S; Skacel, T; Nekljudova, V; Lück, H J; Schwenkglenks, M; Brodowicz, T; Zielinski, C; von Minckwitz, G (2011). Evaluating the impact of Relative Total Dose Intensity (RTDI) on patients' short and long-term outcome in taxane- and anthracycline-based chemotherapy of metastatic breast cancer- a pooled analysis. BMC Cancer, 11:131.

Matter-Walstra, K; Schwenkglenks, M; Szucs, T D; Pestalozzi, B (2011). How to get involved in a health economic analysis: an introduction for clinical researchers. Schweizer Krebs-Bulletin = Bulletin Suisse du Cancer, 31(2):144-146.

Pettengell, R; Schwenkglenks, M (2011). Incidence of neutropenia, chemotherapy delivery, and use of colony-stimulating factor in patients with non-Hodgkin lymphoma of different age groups. Leukemia and Lymphoma, 52(6):1133-1136.

Egevad, L; Algaba, F; Berney, D M; Boccon-Gibod, L; Compérat, E; Evans, A J; Grobholz, R; Kristiansen, G; Langner, C; Lockwood, G; Lopez-Beltran, A; Montironi, R; Oliveira, P; Schwenkglenks, M; Vainer, B; Varma, M; Verger, V; Camparo, P (2011). Interactive digital slides with heat maps: a novel method to improve the reproducibility of Gleason grading. Virchows Archiv, 459(2):175-182.

Blank, P R; Moch, H; Szucs, T D; Schwenkglenks, M (2011). KRAS and BRAF mutation analysis in metastatic colorectal cancer: a cost-effectiveness analysis from a Swiss perspective. Clinical Cancer Research, 17(19):6338-6346.

Pettengell, R; Schwenkglenks, M; Bacon, P; Lawrinson, S; Duehrsen, U (2011). Pegfilgrastim primary prophylaxis in patients with non-Hodgkin lymphoma: results from an integrated analysis. Hematological Oncology, 29(4):177-184.

Szucs, T D; Blank, P R; Schwenkglenks, M; Aapro, M (2011). Potential health economic impact of intravenous iron supplementation to erythropoiesis-stimulating agent treatment in patients with cancer- or chemotherapy-induced anemia. Oncology, 81(1):45-49.

Schwenkglenks, M; Pettengell, R; Jackisch, C; Paridaens, R; Constenla, M; Bosly, A; Szucs, T D; Leonard, R (2011). Risk factors for chemotherapy-induced neutropenia occurrence in breast cancer patients: data from the INC-EU Prospective Observational European Neutropenia Study. Supportive Care in Cancer, 19(4):483-490.

Aapro, M; Schwenkglenks, M; Lyman, G H; Lopez Pousa, A; Lawrinson, S; Skacel, T; Bacon, P; von Minckwitz, G (2010). Pegfilgrastim primary prophylaxis vs. current practice neutropenia management in elderly breast cancer patients receiving chemotherapy. Critical Reviews in Oncology / Hematology, 74(3):203-210.

Schwenkglenks, M; Pettengell, R; Szucs, T D; Culakova, E; Lyman, G H (2010). Hodgkin lymphoma treatment with ABVD in the US and the EU: neutropenia occurrence and impaired chemotherapy delivery. Journal of Hematology and Oncology, 3:27.

Blank, P R; Schwenkglenks, M; Moch, H; Szucs, T D (2010). Human epidermal growth factor receptor 2 expression in early breast cancer patients: a Swiss cost-effectiveness analysis of different predictive assay strategies. Breast Cancer Research and Treatment, 124(2):497-507.

Romanens, M; Ackermann, F; Spence, J; Darioli, R; Rodondi, N; Corti, R; Noll, G; Schwenkglenks, M; Pencina, M (2010). Improvement of cardiovascular risk prediction: time to review current knowledge, debates, and fundamentals on how to assess test characteristics. European Journal of Cardiovascular Prevention and Rehabilitation, 17(1):18-23.

Matter-Walstra, K W; Dedes, K J; Schwenkglenks, M; Brauchli, P; Szucs, T D; Pestalozzi, B C (2010). Trastuzumab beyond progression: a cost-utility analysis. Annals of Oncology, 21(11):2161-2168.

Schwenkglenks, M; Romanens, M (2010). Vergleichbarkeit der von Schweizer Ärztinnen und Ärzten verursachten Behandlungskosten in der Grundversorgung. Schweizerische Ärztezeitung, 91(35):1343-1346.

Dedes, K J; Matter-Walstra, K; Schwenkglenks, M; Pestalozzi, B C; Fink, D; Brauchli, P; Szucs, T D (2009). Bevacizumab in combination with paclitaxel for HER-2 negative metastatic breast cancer: an economic evaluation. European Journal of Cancer, 45(8):1397-1406.

von Minckwitz, G; Schwenkglenks, M; Skacel, T; Lyman, G H; Lopez Pousa, A; Bacon, P; Easton, V; Aapro, M S (2009). Febrile neutropenia and related complications in breast cancer patients receiving pegfilgrastim primary prophylaxis versus current practice neutropaenia management: results from an integrated analysis. European Journal of Cancer, 45(4):608-617.

Romanens, M; Ackermann, F; Abay, M; Szucs, T; Schwenkglenks, M (2009). Agreement of Swiss-adapted international and European guidelines for the assessment of global vascular risk and for lipid lowering interventions. Cardiovascular Drugs and Therapy, 23(3):249-254.

Blank, P R; Schwenkglenks, M; Szucs, T D (2009). Disparities in Influenza Vaccination Coverage Rates by Target Group in Five European Countries: Trends Over Seven Consecutive Seasons. Infection, 37(5):390-400.

McCann, S; Schwenkglenks, M; Bacon, P; Einsele, H; D'Addio, A; Maertens, J; Niederwieser, D; Rabitsch, W; Roosaar, A; Ruutu, T; Schouten, H; Stone, R; Vorkurka, S; Quinn, B; Blijlevens, N (2009). The Prospective Oral Mucositis Audit: relationship of severe oral mucositis with clinical and medical resource use outcomes in patients receiving high-dose melphalan or BEAM-conditioning chemotherapy and autologous SCT. Bone Marrow Transplantation, 43(2):141-147.

Blank, P R; Schwenkglenks, M; Szucs, T D (2009). Vaccination coverage rates in eleven European countries during two consecutive influenza seasons. Journal of Infection, 58(6):441-453.

Pettengell, R; Bosly, A; Szucs, T D; Jackisch, C; Leonard, R; Paridaens, R; Constenla, M; Schwenkglenks, M (2008). Multivariate analysis of febrile neutropenia occurrence in patients with non-Hodgkin lymphoma: data from the INC-EU Prospective Observational European Neutropenia Study. British Journal of Haematology, 144(5):677-685.

Schwenkglenks, M. Rational Allocation of Limited Health Care Resources: The Contributions of Epidemiological, Clinical, and Health Economic Studies. 2008, University of Zurich, Faculty of Medicine.

Blank, P R; Freiburghaus, A U; Schwenkglenks, M; Szucs, T D; Kunze, U (2008). Influenza vaccination coverage rates in Austria in 2006/07 - a representative cross-sectional telephone survey. Wiener Medizinische Wochenschrift, 158(19-20):583-588.

Blank, P R; Schwenkglenks, M; Szucs, T D (2008). Influenza vaccination coverage rates in five European countries during season 2006/07 and trends over six consecutive seasons. BMC Public Health, 8:272.

Pettengell, R; Schwenkglenks, M; Leonard, R; Bosly, A; Paridaens, R; Constenla, M; Szucs, T D; Jackisch, C (2008). Neutropenia occurrence and predictors of reduced chemotherapy delivery: results from the INC-EU prospective observational European neutropenia study. Supportive Care in Cancer, 16(11):1299-1309.

Blank, P R; Freiburghaus, A U; Schwenkglenks, M; Szucs, T D (2008). Trends in influenza vaccination coverage rates in the United Kingdom over six seasons from 2001-2 to 2006-7. Euro Surveillance, 13(43):1-7.

Szucs, T D; Holm, M V; Schwenkglenks, M; Zhang, Z; Weintraub, W S; Burnier, M; Erne, P (2006). Cost-effectiveness of eplerenone in patients with left ventricular dysfunction after myocardial infarction - an analysis of the EPHESUS study from a Swiss perspective. Cardiovascular Drugs and Therapy, 20(3):193-204.

Schwenkglenks, M; Jackisch, C; Constenla, M; Kerger, J N; Paridaens, R; Auerbach, L; Bosly, A; Pettengell, R; Szucs, T D; Leonard, R (2006). Neutropenic event risk and impaired chemotherapy delivery in six European audits of breast cancer treatment. Supportive Care in Cancer, 14(9):901-909.

Schwenkglenks, M; Preiswerk, G; Lehner, R; Weber, F; Szucs, T D (2006). Economic efficiency of gate-keeping compared with fee for service plans: a Swiss example. Journal of Epidemiology & Community Health, 60(1):24-30.

Schwenkglenks, M; Lippuner, K; Häuselmann, H J; Szucs, T D (2005). A model of osteoporosis impact in Switzerland 2000–2020. Osteoporosis International, 16(6):659-671.

Szucs, T D; Schwenkglenks, M; Lüscher, T F; Eberli, F (2005). Die Wirtschaftlichkeit beschichteter Stents in der interventionellen Kardiologie - eine gesamtschweizerische Analyse. Kardiovaskuläre Medizin, 8:41-52.

This list was generated on Mon Jun 17 13:26:16 2019 CEST.